# Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

> **NCT01338818** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 299 (actual)

## Conditions studied

- Attention Deficit/Hyperactivity Disorder

## Interventions

- **DRUG:** Ritalin LA (methylphenidate hydrochloride extended release)

## Key facts

- **NCT ID:** NCT01338818
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2014-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338818, "Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01338818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*